HomeCompareBJGBF vs PFE

BJGBF vs PFE: Dividend Comparison 2026

BJGBF yields 38461.54% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BJGBF wins by $3.5047453194285434e+22M in total portfolio value
10 years
BJGBF
BJGBF
● Live price
38461.54%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.5047453194285434e+22M
Annual income
$34,869,111,860,403,882,000,000,000,000.00
Full BJGBF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BJGBF vs PFE

📍 BJGBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBJGBFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BJGBF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BJGBF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BJGBF
Annual income on $10K today (after 15% tax)
$3,269,230.77/yr
After 10yr DRIP, annual income (after tax)
$29,638,745,081,343,300,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BJGBF beats the other by $29,638,745,081,343,300,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BJGBF + PFE for your $10,000?

BJGBF: 50%PFE: 50%
100% PFE50/50100% BJGBF
Portfolio after 10yr
$1.7523726597142717e+22M
Annual income
$17,434,555,930,201,941,000,000,000,000.00/yr
Blended yield
99.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BJGBF
No analyst data
Altman Z
0.3
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BJGBF buys
0
PFE buys
0
No recent congressional trades found for BJGBF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBJGBFPFE
Forward yield38461.54%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$3.5047453194285434e+22M$49.6K
Annual income after 10y$34,869,111,860,403,882,000,000,000,000.00$26,258.71
Total dividends collected$3.5035733915069485e+22M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BJGBF vs PFE ($10,000, DRIP)

YearBJGBF PortfolioBJGBF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$3,856,854$3,846,153.85$9,153$693.39+$3.85MBJGBF
2$1,390,486,951$1,386,360,117.24$8,593$849.25+$1390.48MBJGBF
3$468,605,187,973$467,117,366,935.83$8,336$1,066.78+$468605.18MBJGBF
4$147,625,030,644,438$147,123,623,093,306.88$8,437$1,384.80+$147625030.64MBJGBF
5$43,474,277,650,870,744$43,316,318,868,081,190.00$9,013$1,875.40+$43474277650.86MBJGBF
6$11,968,270,987,896,644,000$11,921,753,510,810,212,000.00$10,306$2,680.72+$11968270987896.63MBJGBF
7$3,080,100,013,539,240,000,000$3,067,293,963,582,191,000,000.00$12,820$4,101.38+$3080100013539240.00MBJGBF
8$741,038,587,172,289,600,000,000$737,742,880,157,802,600,000,000.00$17,673$6,826.70+$741038587172289664.00MBJGBF
9$166,674,143,814,537,900,000,000,000$165,881,232,526,263,560,000,000,000.00$27,543$12,591.86+$166674143814537904128.00MBJGBF
10$35,047,453,194,285,434,000,000,000,000$34,869,111,860,403,882,000,000,000,000.00$49,560$26,258.71+$3.5047453194285434e+22MBJGBF

BJGBF vs PFE: Complete Analysis 2026

BJGBFStock

Beijing Gas Blue Sky Holdings Limited, an investment holding company, engages in the sale and distribution of natural gas and other related products in the People's Republic of China. It operates through Natural Gas Refuelling Station; Trading and Distribution of Natural Gas; Direct Supply to Industrial Users; and City Gas, Pipeline Construction Fee, Value-Added Service and Others segments. The company operates compressed natural gas (CNG) and liquefied natural gas (LNG) refueling stations for vehicles; and distributes and trades in CNG, LNG fuel oil and other related oil by-products as a wholesaler to industrial and commercial users through direct supply facilities. It also sells natural gas to residential, industrial, and commercial users through pipelines. In addition, the company is involved in the provision of repair and maintenance, and pipeline construction. The company owns 29 gas refueling stations, including 17 CNG refueling stations and 12 LNG refueling stations. The company was formerly known as Blue Sky Power Holdings Limited and changed its name to Beijing Gas Blue Sky Holdings Limited in January 2017. Beijing Gas Blue Sky Holdings Limited was founded in 2000 and is headquartered in Central, Hong Kong.

Full BJGBF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BJGBF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BJGBF vs SCHDBJGBF vs JEPIBJGBF vs OBJGBF vs KOBJGBF vs MAINBJGBF vs JNJBJGBF vs MRKBJGBF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.